2-fluoro-4-(trifluoromethyl)phenyl isocyanate | 114973-27-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-fluoro-4-(trifluoromethyl)phenyl isocyanate
• 英文别名: 2-fluoro-1-isocyanato-4-(trifluoromethyl)benzene；Benzene, 2-fluoro-1-isocyanato-4-(trifluoromethyl)-
• CAS: 114973-27-2
• 化学式: C₈H₃F₄NO
• 分子量: 205.112
• InChiKey: IVRQEHRFUAUDFX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  29.4
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-fluoro-4-(trifluoromethyl)phenyl isocyanate 、 Benzenamine, 3-[5-bromo-1-[(4-methylphenyl)sulfonyl]-1H-pyrrolo[2,3-b]pyridin-3-yl]- 以 四氢呋喃 为溶剂， 生成 1-(3-(5-bromo-1-tosyl-1H-pyrrolo[2,3-b]pyridin-3-yl)phenyl)-3-(2-fluoro-4-(trifluoromethyl)phenyl)urea
  参考文献：
  名称：

  Discovery of 3,5-disubstituted-1H-pyrrolo[2,3-b]pyridines as potent inhibitors of the insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase

  摘要：

  Exploration of the SAR around a series of 3,5-disubstituted-1H-pyrrolo[2,3-b]pyridines led to the discovery of novel pyrrolopyridine inhibitors of the IGF-1R tyrosine kinase. Several compounds demonstrated nanomolar potency in enzyme and cellular mechanistic assays.

  DOI：

  10.1016/j.bmcl.2008.12.110
• 作为产物：
  描述：

  三光气 、 2-氟-4-(三氟甲基)苯胺 在 三乙胺 作用下， 以 甲苯 为溶剂， 生成 2-fluoro-4-(trifluoromethyl)phenyl isocyanate
  参考文献：
  名称：

  Discovery of Novel 4-Hydroxyquinazoline Derivatives: In Silico, In Vivo and In Vitro Studies Using Primary PARPi-Resistant Cell Lines

  摘要：

  A series of novel 4-Hydroxyquinazoline derivatives were designed and synthesized to enhance sensitivity in primary PARPi-resistant cells. Among them, the compound B1 has been found to have superior cytotoxicity in primary PARPi-resistant HCT-15 and HCC1937 cell lines, and dose-dependently suppressed the intracellular PAR formation and enhanced the γH2AX aggregation. Mechanistic study showed that B1 stimulated the formation of intracellular ROS and the depolarization of the mitochondrial membrane, which could increase apoptosis and cytotoxicity. An in vivo study showed that B1 significantly suppressed tumor growth at a dose of 25 mg/kg, and an acute toxicity study confirmed its safety. Molecular docking and dynamics simulations revealed that hydrogen bonding between B1 and ASP766 may be helpful to enhance anti-drug resistance ability. This study suggests that B1 is a potent PARP inhibitor that can overcome PARPi resistance and deserves further investigation.

  DOI：

  10.3390/molecules29061407

文献信息

• DISUBSTITUTED PHTHALAZINE HEDGEHOG PATHWAY ANTAGONISTS
  申请人：Bastian Jolie Anne

  公开号：US20110190304A1

  公开（公告）日：2011-08-04

  The present invention provides novel 1,4-disubstituted phthalazine hedgehog pathway antagonists useful in the treatment of cancer.

  本发明提供了一种新型的1,4-二取代邻苯二酮刺猬途径拮抗剂，可用于治疗癌症。
• Benzoyl (thio) harnstoffe
  申请人：BAYER AG

  公开号：EP0268943A1

  公开（公告）日：1988-06-01

  Die vorliegende Erfindung betrifft die neuen substitu­ierten Benzoyl(thio)harnstoffe der allgemeinen Formel (I) in welcher X für Sauerstoff oder Schwefel steht, R¹ für Halogen steht und R² für Halogen steht, welche als Schädlingsbekämpfungsmittel verwendet werden können.

  本发明涉及通式（I）中 X 为氧或硫、R¹ 为卤素、R² 为卤素的新的取代苯甲酰（硫代）脲，可用作杀虫剂。
• Novel Pyrrolidine Ureas as C−C Chemokine Receptor 1 (CCR1) Antagonists
  作者：J. Robert Merritt、Jinqi Liu、Elizabeth Quadros、Michelle L. Morris、Ruiyan Liu、Rui Zhang、Biji Jacob、Jennifer Postelnek、Catherine M. Hicks、Weiqing Chen、Earl F. Kimble、W. Lynn Rogers、Linda O’Brien、Nicole White、Hema Desai、Shalini Bansal、George King、Michael J. Ohlmeyer、Kenneth C. Appell、Maria L. Webb

  DOI：10.1021/jm801416q

  日期：2009.3.12

  Monocyte infiltration is implicated in a variety of diseases including multiple myeloma, rheumatoid arthritis, and multiple sclerosis. C-C chemokine receptor 1 (CCR1) is a chemokine receptor that upon stimulation, particularly by macrophage inflammatory protein 1 alpha (MIP-1 alpha) and regulated on normal T-cell expressed and secreted (RANTES), mediates monocyte trafficking to sites of inflammation. High throughput screening of our combinatorial collection identified a novel, moderately potent CCR1 antagonist 3. The library hit 3 was optimized to the advanced lead compound 4. Compound 4 inhibited CCR1 mediated chemotaxis of monocytes with an IC50 of 20 nM. In addition, the compound was highly selective over other chemokine receptors. It had good microsomal stability when incubated with rat and human liver microsomes and showed no significant cytochrome P450 (CYP) inhibition. Pharmacokinetic evaluation of the compound in the rat showed good oral bioavailability.
• US4782091A
  申请人：——

  公开号：US4782091A

  公开（公告）日：1988-11-01
• US8404687B2
  申请人：——

  公开号：US8404687B2

  公开（公告）日：2013-03-26